Allergan’s (NYSE:AGN) Forest Laboratories subsidiaries have reached agreement to settle a class action lawsuit brought by buyers of Alzheimer’s med Namenda (memantine) for $750M.
The litigation pertained to alleged anticompetitive activity, specifically, efforts by Forest to delay/impair generic competition.
The company says the settlement makes no admission of wrongdoing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.